BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

  In Q3 of 2017, the Company recorded $10.9 million in product revenues from Sandoz’s sales of Glatopa 20 mg compared to $23.3 million for the same period in 2016.

  November 1, 2017

   · 

  14 min read
• Drug Development

  Resverlogix Announces Fifth Positive Recommendation From Data Safety Monitoring Board for Phase III Study of Apabetalone

  A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without any modification.

  November 1, 2017

   · 

  3 min read
• Drug Development

  AbbVie Announces Positive Phase III Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis With Associated Pain

  In the extension studies, elagolix demonstrated sustained reduction in average monthly menstrual pelvic pain and non-menstrual pelvic pain in women through the 12-month treatment period.

  November 1, 2017

   · 

  10 min read
• Business

  iCAD to Report Third Quarter 2017 Financial Results on Wednesday, November 8

  The company will release financial results for the three and nine months ended September 30, 2017 after the close of the market.

  November 1, 2017

   · 

  3 min read
• Business

  Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 15, 2017

  The company will report its financial results for the three and nine months ended September 30, 2017.

  November 1, 2017

   · 

  1 min read
• Genetown

  Takeda to Showcase Data That May Reshape the Future of Blood Cancer Treatments During 59th ASH Annual Meeting

  Eleven Takeda-sponsored abstracts were accepted for presentation during ASH 2017.

  November 1, 2017

   · 

  41 min read
• Genetown

  Intellia Therapeutics Announces Proposed Public Offering of Common Stock

  Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock.

  November 1, 2017

   · 

  3 min read
• Business

  GB Sciences Inducts Scientific Advisory Board: Dr. Andrea Small-Howard of GB Sciences, Dr. Helen Turner of Chaminade University, Dr. Norbert Kaminsky of Michigan State University, and Dr. Carlos Ríos-Bedoya of McLaren Health

  GB Sciences inducts a Scientific Advisory Board to provide oversight for product development within GB Sciences’ intellectual property portfolio.

  November 1, 2017

   · 

  4 min read
• Business

  Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call

  The call will cover an update on Merrimack’s recent progress as well as a summary of third quarter 2017 financial results.

  November 1, 2017

   · 

  2 min read
• Policy

  Prometic Receives Clearance From the Swedish Medical Products Agency to Initiate Plasminogen Clinical Trial in Chronic Tympanic Membrane Perforation

  ProMetic today announced that it has received Swedish MPA CTA approval to commence a clinical trial of its plasminogen therapy in patients suffering from chronic TMP.

  November 1, 2017

   · 

  4 min read